Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02844712
Other study ID # 9394
Secondary ID
Status Terminated
Phase N/A
First received July 15, 2016
Last updated July 25, 2016
Start date December 2014
Est. completion date November 2016

Study information

Verified date July 2016
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority France: Committee for the Protection of Personnes
Study type Interventional

Clinical Trial Summary

Patients with a complete drug allergy work-up to betalactam antibiotics were contacted (by mail) and asked to answer a questionnaire regarding the tolerance upon readministration of a negatively tested beta-lactam.


Recruitment information / eligibility

Status Terminated
Enrollment 750
Est. completion date November 2016
Est. primary completion date May 2016
Accepts healthy volunteers No
Gender Both
Age group 5 Years and older
Eligibility Inclusion Criteria:

- Elderly patients with at least 5 years at the time of consultation for allergy suspected allergy to beta-lactam antibiotics in the University Hospital of Montpellier and with a negative provocation test to a betalactam

- The patient or the patient's legal representatives are not their opposition to participate in this study

- The patient must be affiliated or beneficiary in a health insurance system

Exclusion Criteria:

- The patient is exclusion period determined by a previous study

- The patient is under judicial protection, guardianship or curatorship

- The patient or the patient's legal representatives do not read fluently the French language

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research


Related Conditions & MeSH terms


Intervention

Other:
Evaluation of reexposure to a negatively tested betalactam


Locations

Country Name City State
France Allergy Unit, Arnaud de Villeneuve Hospital, University Hospital of Montpellier Montpellier

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Negative predictive value of drug provocation tests to betalactams one day Yes
Secondary The types of reactions upon reexposure to a negatively tested betalactam one day Yes
See also
  Status Clinical Trial Phase
Completed NCT02839551 - Optimal Doses for Drug Provocation Tests to Beta-lactams N/A
Completed NCT00198419 - Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) Phase 1
Completed NCT02839811 - Medical Device for Drug Allergy Diagnosis N/A
Completed NCT02983630 - Allergy Testing of Patients Labeled as Penicillin Allergic N/A
Completed NCT00198458 - Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) Phase 1
Recruiting NCT04330118 - Origin and Function of Eosinophilic Polynuclear During DRESS Syndrome
Completed NCT04421638 - Cephalosporin Hypersensitivity
Recruiting NCT02031120 - Management of Drug Hypersensitivity in Children N/A
Completed NCT01276314 - Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions N/A
Terminated NCT00505648 - Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin) Phase 3
Completed NCT03158831 - Drug Challenges Without Prior Skin Testing Phase 1
Completed NCT03076749 - Predictive Models for Betalactam Allergy N/A
Active, not recruiting NCT06428162 - An Evaluation of Healthcare Providers' Adherence to Pharmacovigilance Practices in an African Community
Completed NCT03743220 - Drug Provocation Test (DPT) to Non Steroidal Anti-inflammatory Drugs (NSAID)
Completed NCT03771118 - Drug Provocation Test (DPT) to Paracetamol
Not yet recruiting NCT06406114 - Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing Phase 2
Completed NCT05269082 - A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood of Children, Teenagers and Adults
Completed NCT04827602 - Drug Allergy Labels After Drug Allergy Investigation